This time the setting is a small college, where a wealthy and abrasive major benefactor has rubbed lots of people the wrong way. The school administrators come to the detective agency run by Julie — ...

Nurix Therapeutics recently announced the initiation of the pivotal Phase 2 DAYBreak trial of its BTK degrader candidate NX-5948 in relapsed or refractory chronic lymphocytic leukemia, alongside plans ...

Ryujinx fork Kenji-NX just released its first major update in more than four months. The Nintendo Switch emulator now offers compatibility with Silksong and more. The update is now available on ...

Choosing between the two most popular Lexus models is surprisingly tricky. Lexus is soon set to end production of sporty, stylish models like the IS, RC, and LC. All have been available with V8 power ...

Nextorage has expanded its product line with the launch of two M.2 SSD enclosures aimed at users who need fast external storage with advanced features. The flagship model, NX-EN1PRO, targets ...

Building products company Quanex (NYSE:NX) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 76.7% year on year to $495.3 million. On the other hand, the company’s full-year revenue ...

Two children were killed and 17 people were injured — 14 of them children — in a shooting Wednesday morning at a Minneapolis Catholic school, as students, staff and parishioners were gathered for a ...

Nintendo Switch emulator Kenji-NX got its first big update on Android. Update 2.0.4 has bug fixes and UI updates, plus Android-only features. The Ryujinx fork is a top performer on Snapdragon 8 Elite ...

Lexus struck luxury SUV gold when it introduced the RX back in 1998. After the RX grew into a midsize SUV, Lexus added the NX to its lineup to compete in the fought-over luxury compact SUV segment. A ...

When she first played World of Warcraft at 10 years old, Ophélie knew her future would be in the video game industry. With a passion for writing and playing video games, she naturally became a gaming ...

Nurix Therapeutics announced that its collaboration partner, Gilead Sciences, will commence a Phase 1 clinical trial for the IRAK4 degrader GS-6791/NX-0479 in healthy volunteers in Q2 2025 following ...